Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

33P - Anti-tumor effect of vaccination with PDT-treated tumor cells


16 Sep 2021


ePoster Display


Cytotoxic Therapy;  Clinical Research;  Cancer Biology

Tumour Site


Vladimir Klimenko


Annals of Oncology (2021) 32 (suppl_5): S361-S375. 10.1016/annonc/annonc684


V.V. Klimenko1, N.A. Verlov1, V.S. Burdakov2, A.A. Bogdanov1, I.N. Terterov1, N.A. Knyazev1, V.M. Moiseyenko1, A.A. Bogdanov1

Author affiliations

  • 1 Scientific Department, St. Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care (Oncological), 197758 - St Petersburg/RU
  • 2 Molecular And Radiation Biophysics, Petersburg Nuclear Physics Institute NRC Kurchatov Institute, 188300 - Leningradskaya Oblast, Gatchina/RU


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 33P


Tumor cells death induced by photodynamic therapy (PDT) drives to inflammation and antigens release and can activate specific anti-tumor immune response. In this work, we demonstrated the in vivo effect of vaccination with PDT-treated tumor cells.


PDT anti-tumor vaccines were obtained by continuous wave (CW) or pulse mode (PM) 662 nm laser irradiation (light dose: 4, 8 J/cm2; fluence rate: 50 mW/cm2) of mouse cervical cancer cells (RShM-5, 5x105 cells) preliminarily treated with chlorine e6 based photosensitizer Radachlorin (PS; concentration: 7 mkg/ml, 10 mkg/ml). Cell viability were assessed using Annexin V-FITC/PI assay and analyzed by flow cytometry. After 24 h PDT-treated RShM-5 cells (1.25x105 cells) were harvested and subcutaneous injected into right flank of CBA mice. 8 days after vaccination mice were subcutaneous injected with 5x105 live RShM-5 cells in another flank. The size of the initiated tumor node in the challenge site was monitored up to 70 days after the inoculation. The survival rate was assessed in the control group (CG n=10), CW PDT group (CWG, n=9), PM PDT group (PMG, n=9) and freeze-thaw cell lysis group (FTG, n=9). Mice were sacrificed when the tumor volume exceeded 4 cm3.


On the 70th day after inoculation with live RShM-5 cells, the tumor-free survival probability was 67 % in PMG, 33 % in CWG, 22 % in FTG and 0 % in CG. At light dose 4 J/cm2 and PS concentration 7 mkg/ml number of dying but not dead PM PDT-treated RShM-5 cells was much more then in case of light dose 8 J/cm2 and PS concentration 10 mkg/ml. These PDT-treated RShM-5 cells induced better tumor-free survival probability.


Vaccination with PM PDT-treated RShM-5 cells resulted in the best anti-tumor effect in vivo. PM PDT-treated tumor cells have greater immunogenic potential. Very likely that for the best immunogenic effect of PDT-generated vaccines they must contain predominant amount of dying but not dead tumor cells.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.